key: cord-0257078-dyxyab5g
authors: Lamers, Mart M.; Mykytyn, Anna Z.; Breugem, Tim I.; Groen, Nathalie; Knoops, Kèvin; Schipper, Debby; van Acker, Romy; van den Doel, Petra B.; Bestebroer, Theo; Koopman, Charlotte D.; Reusken, Chantal; Muraro, Mauro J.; GeurtsvanKessel, Corine H.; van Royen, Martin E.; Peters, Peter J.; Zhang, Jingshu; Haagmans, Bart L.
title: SARS-CoV-2 Omicron efficiently infects human airway, but not alveolar epithelium
date: 2022-01-20
journal: bioRxiv
DOI: 10.1101/2022.01.19.476898
sha: a230aaea0014244c30f3cb964e5ddee67098c7bd
doc_id: 257078
cord_uid: dyxyab5g

In late 2021, the highly mutated SARS-CoV-2 Omicron variant emerged, raising concerns about its potential extensive immune evasion, increased transmissibility and pathogenicity. Here, we used organoids of the human airways and alveoli to investigate Omicron’s fitness and replicative potential in comparison with earlier SARS-CoV-2 variants. We report that Omicron replicates more rapidly in the airways and has an increased fitness compared to the early 614G variant and Delta. In contrast, Omicron did not replicate productively in human alveolar type 2 cells. Mechanistically, we show that Omicron does not efficiently use TMPRSS2 for entry or spread through cell-cell fusion. Altogether, our data show that Omicron has an altered tropism and protease usage, potentially explaining its higher transmissibility and decreased pathogenicity.

By confocal microscopy we observed that Omicron and Delta infected predominantly ciliated 116 cells, similar to previous reports on 614G ( Fig. 2A ) (26-28, 30, 31) . We confirmed that at day 117 2 post-infection, Omicron infected more cells than Delta (Fig. 2B, D) , whereas higher 118 infection rates were observed at day 3 for Delta ( Fig. 2C, E) . At day 10 post-infection, 119 similar levels of infection were seen for Delta and Omicron, whereas 614D and 614G were 120 both cleared (Fig. 2F) .

Omicron rapidly outcompetes 614G, and has a fitness advantage over Delta in the first 123 days of the infection 124 Next, we investigated which VOCs had the highest fitness in airway cells. For this purpose, 125 we infected airway organoids with a mixture of 614G, Alpha, Delta or Omicron at a ratio of 126 1:1 or 5:1 (cumulative moi = 0.1). We sampled the cultures daily for 10 days and determined 127 the relative frequency of both viruses to calculate replicative fitness using Sanger sequencing 128 and electropherogram peak analyses (32) (Fig. 3A) . These experiments clearly indicated that 129 both the Alpha variant ( Fig. 3B-C, Fig. S2A -B) and the Delta variant ( Fig. 3D-E, Fig. S2C -130 D) had an increased replicative fitness in the human airway. In addition, we found that there 131 was a minimal fitness difference between Alpha and Delta, slightly in favor of the latter (Fig.   132 S2E-F), suggesting that Delta's antigenic drift significantly contributed to its transmissibility. 133 134 Omicron has outcompeted Delta in many countries within weeks after the initial introduction, 135 indicating that it has a high fitness (10, 14-16). Omicron rapidly outcompeted 614G (Fig. 3F-136 G, Fig. S2G-H ). Next, we tested whether Omicron could outcompete Delta. Interestingly, 137 Omicron had a higher fitness than Delta in the first 5 days of the infection, after which Delta 138 outcompeted Omicron (Fig. 2G-H, Fig. S2I-J) . These data again confirm that Omicron 139 replicates more rapidly in the initial days of the infection (Fig. 1F-G; Fig. 2B -E) and that 140 both viruses are phenotypically distinct. As infected individuals are most infectious in the 141 first days of the infection (29, 33, 34) , these data may explain why Omicron has rapidly 142 outcompeted Delta in many countries. In addition, the infectious period is likely shortened by 143 neutralizing antibodies induced upon (re-)infection or vaccination (35, 36) . To test whether 144 antibodies induced upon vaccination could affect the fitness of Omicron, we added serum 145 (1%) from a vaccinated individual (2x mRNA-1273) in the lower compartment of the air- 146 liquid interface 2D organoid wells, potentially allowing IgA antibodies to be transferred to 147 the top compartment. Medium with serum was refreshed daily. This serum effectively 148 neutralized Delta (IC50:2657), but had a low activity against Omicron (IC50:123.5), which is 149 in line with recent findings on vaccine recipient serum responses against Omicron (11, 17, 150 21, 22, 25, 37) . In this system, Omicron's fitness increased and completely outcompeted 151 Delta on day 1-3 ( Fig. 3J-K) . In the following days Omicron remained at a higher frequency 152 until day 9, but Delta did come up slowly from day 4-10. These findings indicate that 153 Omicron has an initial fitness advantage over Delta, and that this advantage is likely 154 increased due to (population) immunity. They also indicate that Delta and Omicron may have 155 evolved different strategies to evade neutralizing antibodies. 156 157 Omicron does not efficiently spread through cell-cell fusion 158 SARS-CoV-2 can spread from cell to cell by fusion of infected cells with neighboring cells 159 using the S protein, leading to the formation of large multi-nucleated syncytial cells (38, 39) . 160 The relevance of cell-cell spread is still being investigated, but it has been linked to antibody 161 evasion, virus dissemination and pathogenicity (40, 41). As Delta could still outcompete 162 Omicron late in infection in the presence of neutralizing serum with a high anti-Delta activity 163 ( Fig. 3J-K) , we hypothesized that Delta may spread more efficiently through cell-cell fusion 164 than Omicron. In airway organoids, we noticed that Delta resulted in abundant syncytial 165 cells, whereas Omicron did not ( Fig. 4A-B) , showing that indeed Delta is more fusogenic. 166 Using a GFP-complementation system and S protein overexpression (42) (Fig. 4C) we 167 observed that the Delta S was more fusogenic compared to 614G in VeroE6, VeroE6-168 TMPRSS2 and Calu-3 cells (Fig. 4D-F) . The Omicron S was significantly less fusogenic in 169 all cells. Next, we investigated whether similar results would be obtained using an authentic 170 virus fusion assay, also based on GFP complementation in Calu-3 cells (Fig. 4G) . In this Omicron is less dependent on TMPRSS2 for entry and has evolved to use an alternative 179 protease in airway cells 180 SARS-CoV-2 S is proteolytically cleaved to activate the S protein for fusion. This occurs in 181 producing cells at the S1/S2 site by furin, and at a site directly adjacent to the fusion peptide 182 by TMPRSS2 at the cell surface or cathepsins in the endosome (45, 46). Coronavirus tropism 183 is mainly influenced by receptor and protease usage (43, 44). Therefore, we first investigated 184 whether Omicron uses TMPRSS2 for entry. For this purpose, we used a S-based VSV 185 pseudovirus system described before (42) (Fig. 5A) . Omicron was 1-2 log less infectious on 186 VeroE6 cells and 2-3 log less infectious on VeroE6-TMPRSS2 cells (Fig. 5B) . In line with 187 previous data (42, 47), TMPRSS2 expression effectively increased the infectivity of 614G, 188 Alpha and Delta pseudoviruses (Fig. 5B) , but surprisingly Omicron's infectivity was not 189 affected by TMPRSS2. We confirmed this data by investigating the route of entry of 190 Omicron pseudoviruses in cells that have an active TMPRSS2 as well as a cathepsin-191 mediated entry route (42). TMPRSS2-mediated entry was inhibited using serine protease 192 inhibitor camostat and cathepsins were inhibited using E64D (Fig. 5C-D (Fig. 5E) , but was still inhibited by camostat and not E64D (Fig. 5F-G) . These data indicate 199 that entry into Calu-3 cells occurs either inefficiently through TMPRSS2, or is mediated by 200 another serine protease that is blocked by camostat. As we noticed that the S1/S2 cleavage of 201 Omicron pseudovirus (produced on 293T cells) was much lower than authentic virus 202 (produced on Calu-3 cells) (Fig. S3A-D) , we used authentic viruses to verify that Omicron 203 did not benefit from TMPRSS2 and had a lower infectivity on Calu-3 cells (Fig. 5H-I) . 204 Although in this case, pseudovirus and authentic virus data led to the same conclusion, these 205 data indicate that pseudovirus data should be confirmed using authentic viruses. Next, we 206 tested which entry route is used by Omicron and Delta authentic viruses on airway organoids. 207 Both viruses were effectively inhibited by camostat (10 µM), and not E64D (10 µM), or the 208 combination of both ( Fig. 5J-K) , indicating that both viruses use the serine protease and not 209 the cathepsin-mediated entry pathway in relevant cells. These findings were reproduced in a 210 second experiment using a higher camostat concentration (100 µM) ( Fig. S4A-B) . In line 211 with previous work (42), E64D was effective against all viruses in VeroE6 cells ( Fig. S5A- 

B). In addition, these findings, together with the observation that Omicron replicates more 213 efficiently in airway cells compared with Delta and does not efficiently use TMPRSS2, 214 suggest that Omicron has evolved to use another serine protease expressed by airway cells.

Omicron does not efficiently infect AT2 cells 217 The ability of SARS-CoV-2 to infect alveolar type 2 (AT2) cells is thought to be an 218 important virulence factor for SARS-CoV-2, but also SARS-CoV and MERS-CoV, which 219 depend on TMPRSS2 for entry (46). Inflammation in the alveoli likely sets off an 220 inflammatory response ultimately leading to flooding of the alveoli, impeding gas exchange. 221 AT2 cells express TMPRSS2 and removing TMPRSS2 activity effectively reduces pathology 222 in animals for SARS-CoV, SARS-CoV-2 and H7N9 influenza A (50, 51). Until recently 223 studying SARS-CoV-2 pathogenesis in these cells has been difficult due to the lack of an in 224 vitro model, but recently several groups have established organoid models of the human adult 225 alveolus (52-55). As Omicron does not efficiently use TMPRSS2 and preliminary reports 226 have indicated that Omicron might be less pathogenic (56-60), we used an alveolar organoid 227 model (adapted from (52, 53)) ( Fig. S6) to assess whether Omicron could infect AT2 cells 228 ( Fig. 6A-C) . Whereas Delta efficiently replicated in AT2 cultures, Omicron was severely 229 attenuated ( Fig. 6D-E) . These observations were confirmed in AT2 organoids from another 230 donor ( Fig. 6F-G) and supported by confocal microscopy at day 4 post-infection, which 231 showed abundant infection for Delta, but not for Omicron ( Fig. 6H-I) . In line some infectious 232 virus production late in the infection for Omicron, we did observe infected cells in Omicron 233 infected AT2 organoids at day 10 post-infection ( Fig. S7A-B) . Altogether, our data indicate 234 that Omicron does not efficiently infect AT2 cells, whereas airway infection is highly 235 efficient ( Fig. 1-3) .

After nearly two years of circulation and evolution of SARS-CoV-2 in humans, the highly 238 mutated Omicron variant emerged, raising concerns about its potential extensive immune 239 evasion, increased transmissibility and pathogenicity. Here, we used human organoid systems 240 to investigate Omicron's shedding, fitness and replicative potential in the airways and alveoli. 241 We report that Omicron efficiently replicates ciliated cells of the airway and has a higher 242 fitness than 614G and Delta. Mechanistically, Omicron was much less fusogenic and did not 243 efficiently use TMPRSS2 for entry. However, Omicron was inhibited by serine protease 244 inhibitor camostat (and not cathepsin inhibitor E64D) in airway cells indicating that it has 245 evolved to use another serine protease. Our observation that Omicron does not efficiently 246 replicate in AT2 cells suggests that this protease is not present on these cells. Our data are in 247 line with preliminary reports indicating that Omicron's hospitalization rates appear lower 248 than Delta's (56-60). At the same time, our data on Omicron's rapid replication and 249 competitive fitness in the airway support epidemiological observations that Omicron appears 250 to be even more transmissible than Delta (14, 15, 61, 62) . A recent study in hamsters showed 251 that Omicron was attenuated in both the lower and upper respiratory tract (63). Although 252 these data support that Omicron may be less pathogenic, they fail to explain why Omicron 253 spreads so efficiently in humans. Our data imply that human organoid models are well suited 254 for studying viral fitness and pathogenicity, especially when comparing viral variants that are 255 adapting to specific human host factors. Lysotracker-high cells were sorted using a FACS Aria cell sorter (BD biosciences) into 427 AdDF+++ containing 10 µM Y-27632. Cells were pelleted, incubated on ice for 2 min and 428 plated in BME domes in alveolar medium. Y-27632 (10 µM) was added for the first 5 days. 429 Cells were incubated at 37°C in a humidified CO2 incubator and medium was replaced every 430 4-5 days. 431 Sorted and unsorted AT2 organoids were split every 2-3 weeks at a 1:3-1:8 ratio. 432 Organoids were dissociated to small clumps using TrypLE. 433 All centrifugation steps were performed at 400 xg for 3 min. 

The variant gambit: COVID-19's next move

Early transmissibility assessment of the 749 N501Y mutant strains of SARS-CoV-2 in the United Kingdom

Changes in symptomatology, reinfection, and transmissibility associated with the 752 SARS-CoV-2 variant B.1.1.7: an ecological study

Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 754 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study

Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England

Increased transmissibility and global spread of SARS-CoV-2 variants of concern as 758 at

Household transmission of COVID-19 cases associated with SARS-CoV-2 delta variant 760 (B.1.617.2): national case-control study

Evidence for retained spike-binding and neutralizing activity against emerging 762 SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients

Probable Transmission of SARS-CoV-2 Omicron Variant in Quarantine Hotel

CDC COVID-19 Science Briefs

SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited 768 neutralization and requires ACE2 for infection. medRxiv

Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529) -770 highlights Africa's research capabilities, but exposes major knowledge gaps, inequities of vaccine 771 distribution, inadequacies in global COVID-19 response and control efforts

Daily briefing: Omicron coronavirus variant puts scientists on alert

Relative Instantaneous Reproduction Number of Omicron

CoV-2 variant with respect to the Delta variant in Denmark

Relative Reproduction Number of SARS-CoV-2 Omicron (B.1.1.529) Compared 777 with Delta Variant in South Africa

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity 780 against SARS-CoV-2 Omicron variant. medRxiv

Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-782

CoV-2 virus-like particles. medRxiv

The significant immune escape of pseudotyped SARS-CoV-2 variant Omicron

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2 786

Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody 791 responses. bioRxiv

Reduced neutralisation of SARS-CoV-2 omicron B.1.1.529 variant by post-793 immunisation serum

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity 795 against SARS-CoV-2 Omicron variant

Divergent SARS CoV-2 Omicron-specific T-and B-cell responses in 797 COVID-19 vaccine recipients

SARS-CoV-2 productively infects human gut enterocytes

Human airway cells prevent SARS-CoV-2 multibasic cleavage site cell culture 802 adaptation

An organoid-derived bronchioalveolar model for SARS-CoV-2 infection of 804 human alveolar type II-like cells

Duration and key determinants of infectious virus shedding in hospitalized 806 patients with coronavirus disease-2019 (COVID-19)

Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage 808 of COVID-19

Tropism, replication competence, and innate immune responses of the coronavirus 810 SARS-CoV-2 in human respiratory tract and conjunctiva: an analysis in ex-vivo and in-vitro cultures

Spike mutation D614G alters SARS-CoV-2 fitness

Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and 814 analysis of available evidence for asymptomatic and symptomatic COVID-19 cases

Temporal dynamics in viral shedding and transmissibility of COVID-19

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 819 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial

Effect of Vaccination on Transmission of SARS-CoV-2

Omicron likely to weaken COVID vaccine protection

SARS-CoV-2 spreads through cell-to-cell transmission

Syncytia formation by SARS-CoV-2-infected cells

SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody 828 neutralization

Avoiding the void: cell-to-cell spread of human viruses

SARS-CoV-2 entry into human airway organoids is serine protease-mediated and 833 facilitated by the multibasic cleavage site

Coronavirus Spike Protein and Tropism Changes

Host cell proteases: Critical determinants of coronavirus tropism and 837 pathogenesis

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a 839 Clinically Proven Protease Inhibitor

A CRISPR/Cas9 genetically engineered organoid 843 biobank reveals essential host factors for coronaviruses

Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells

Genome-wide CRISPR screen reveals host genes that regulate SARS-CoV-2 infection

Proteolytic processing of Middle East respiratory syndrome coronavirus spikes 849 expands virus tropism

TMPRSS2 is a host factor that is essential for pneumotropism and pathogenicity of 851 H7N9 influenza A virus in mice

TMPRSS2 Contributes to Virus Spread and Immunopathology in the 853 Airways of Murine Models after Coronavirus Infection

Direct derivation of human alveolospheres for SARS-CoV-2 infection modeling 855 and drug screening

Three-Dimensional Human Alveolar Stem Cell Culture Models Reveal Infection 857 Response to SARS-CoV-2

Progenitor identification and SARS-CoV-2 infection in human distal lung 859 organoids

Human Lung Stem Cell-Based Alveolospheres Provide Insights into SARS-CoV-2-861

Mediated Interferon Responses and Pneumocyte Dysfunction

Characteristics and Outcomes of Hospitalized Patients in South Africa During the 863 COVID-19 Omicron Wave Compared With Previous Waves

Decreased severity of disease during the first global omicron variant covid-19 865 outbreak in a large hospital in tshwane, south africa

Covid-19: Hospital admission 50-70% less likely with omicron than delta, but transmission 867 a major concern

Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in 869 South Africa

SARS-CoV-2 variants of concern and variants under investigation in England: 871 technical briefing 33

Serial interval and basic reproduction number of SARS-CoV-2 873 Omicron variant in South Korea

Generation time of the Alpha and Delta SARS-CoV-2 variants

The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease 876 in mice and hamsters

Long-term expanding human airway organoids for disease modeling

CEL-Seq2: sensitive highly-multiplexed single-cell RNA-Seq

Transformation of intestinal stem cells into gastric stem cells on loss of transcription 882 factor Cdx2

Fast and accurate long-read alignment with Burrows-Wheeler transform

Moderated estimation of fold change and dispersion for RNA-seq 886 data with DESeq2

Controlling the False Discovery Rate -a Practical and Powerful Approach 888 to Multiple Testing

Virtual nanoscopy: generation of ultra-large high resolution electron microscopy 890 maps